Summary
This case study details the Accelerator™ Drug Development solution provided by Thermo Fisher Scientific, which aims to streamline preclinical pathways for biotech companies transitioning to First-in-Human (FIH) trials. The document outlines the challenges faced by a biotech sponsor, including insufficiently defined API characterization methods and inefficient study design, which posed a risk of an 18-month delay and over $1M in additional expenses. By collaborating with Thermo Fisher, the sponsor implemented an integrated approach that optimized critical preclinical elements, resulting in a 12-month acceleration in the transition to FIH trials. Key strategies included defining alternative API specifications based on toxicology data, optimizing the FIH study design, and integrating timelines across various development processes. The proactive measures taken not only saved costs but also established a scalable framework to mitigate risks in future clinical programs, ultimately enhancing the sponsor's confidence in advancing their therapeutic development.
